These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30056546)

  • 61. Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.
    Jung SH; Ahn JS; Kim YK; Kweon SS; Min JJ; Bom HS; Kim HJ; Chae YS; Moon JH; Sohn SK; Lee SW; Byun BH; Do YR; Lee JJ; Yang DH
    BMC Cancer; 2015 Mar; 15():198. PubMed ID: 25879747
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The prognostic significance of CD11b
    Yhim HY; Kim JA; Ko SH; Park Y; Yim E; Kim HS; Kwak JY
    Oncotarget; 2017 Nov; 8(54):92289-92299. PubMed ID: 29190915
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
    Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
    Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.
    Reyal Y; Kayani I; Bloor AJC; Fox CP; Chakraverty R; Sjursen AM; Fielding AK; Ben Taylor M; Bishton MJ; Morris EC; Thomson KJ; Russell N; Mackinnon S; Peggs KS
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1234-1241. PubMed ID: 27095691
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Non-Hodgkin's lymphomas: immunologic prognostic studies.
    Hadzi-Pecova L; Petrusevska G; Stojanovic A
    Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study.
    Oh SY; Kwon HC; Kim WS; Park YH; Kim K; Kim HJ; Kwon JM; Lee J; Ko YH; Ahn YC; Oh SJ; Lee SI; Bang SM; Kim JH; Park J; Ryoo BY; Lee SS; Kim HY; Park K; Kim HJ
    Cancer Lett; 2007 Dec; 258(1):90-7. PubMed ID: 17936499
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
    Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS
    Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
    Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
    Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Validation of the Marginal Zone Lymphoma International Prognostic Index.
    Hong J; Cho J; Ko YH; Kim SJ; Kim WS
    Ann Hematol; 2019 Feb; 98(2):457-464. PubMed ID: 30310985
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?
    Etto LY; Silva VC; Inaoka RJ; Costa RP; Alves AC; Colleoni GW
    Leuk Lymphoma; 2007 Mar; 48(3):526-30. PubMed ID: 17454593
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma.
    Wang J; Zhou M; Xu JY; Chen B; Ouyang J
    Onco Targets Ther; 2015; 8():2645-50. PubMed ID: 26425100
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base.
    Olszewski AJ; Winer ES; Castillo JJ
    Cancer Causes Control; 2015 Aug; 26(8):1163-72. PubMed ID: 26054914
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.
    Lim ST; Hee SW; Quek R; Lim LC; Yap SP; Loong EL; Sng I; Tan LH; Ang MK; Ngeow J; Tham CK; Ngo L; Tan MH; Tao M
    Eur J Haematol; 2008 Jan; 80(1):55-60. PubMed ID: 18028433
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment.
    Arcaini L; Colombo N; Passamonti F; Burcheri S; Orlandi E; Brusamolino E; Della Porta M; Rumi E; Montanari F; Pascutto C; Paulli M; Lazzarino M
    Leuk Res; 2006 Mar; 30(3):277-82. PubMed ID: 16112730
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Low T3 syndrome as a predictor of poor prognosis in peripheral T-cell lymphomas.
    Li W; Gao R; Wang W; Tang J; Yin H; Wu J; Liang J; Li Y; Wang L; Li J; Shen H; Xu W
    Clin Transl Oncol; 2024 Mar; 26(3):613-622. PubMed ID: 37460749
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.
    Zumsteg ZS; Zelefsky MJ; Woo KM; Spratt DE; Kollmeier MA; McBride S; Pei X; Sandler HM; Zhang Z
    BJU Int; 2017 Nov; 120(5B):E87-E95. PubMed ID: 28464446
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL).
    Park JH; Kim S; Ryu JS; Lee SW; Park CS; Huh J; Suh C
    Hematol Oncol; 2018 Feb; 36(1):56-61. PubMed ID: 28401574
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients.
    Formica V; Norman AR; Cunningham D; Wotherspoon A; Oates J; Chong G
    Acta Haematol; 2009; 122(4):193-9. PubMed ID: 19887775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.